Immunology and Cell Biology · 2013 · 24 citations · 69 references
Life SciencesImmunologyOncologyImmunoregulationImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCell-mediated ImmunityEffector T Cell FunctionT Cell ActivationT Cell Responses To TumorsCd4 T Cell ActivationCd4+ Tumor-infiltrating LymphocytesCostimulatory Receptor PathwaysEffector T Cell DifferentiationExpansionImmune Cell CostimulationImmune Effector MoleculesT-cell Responses To Tumor Antigens
T-cell tolerance to tumor antigens represents a major hurdle in generating tumor immunity. Combined administration of agonistic monoclonal antibodies (mAbs) to the costimulatory receptors CD134 plus CD137 can program T-cells responding to tolerogenic antigen to undergo expansion, and effector T-cell differentiation, and also elicits tumor immunity. Nevertheless, CD134 and CD137 agonists can also engage inhibitory immune components. To understand how immune stimulatory versus inhibitory components are regulated during CD134 plus CD137 dual costimulation (DCo), the current study utilized a model where DCo programs T-cells encountering a highly tolerogenic self-antigen to undergo effector differentiation. IFN-γ was found to have a pivotal role in maximizing the function of effector T-cells, while simultaneously limiting the expansion of CD4(+)CD25(+)Foxp3(+) Tregs. In antigen-responding effector T-cells, IFN-γ operates via a direct cell-intrinsic mechanism to cooperate with IL-2 to program maximal expression of granzyme B. Simultaneously, IFN-γ limits expression of the IL-2 receptor alpha chain (CD25) and IL-2 signaling through a mechanism that does not involve T-bet-mediated repression of IL-2. IFN-γ also limited CD25 and Foxp3 expression on bystanding CD4(+)Foxp3(+) Tregs, and limited the potential of these Tregs to expand. These effects could not be explained by the ability of IFN-γ to limit IL-2 availability. Taken together, during DCo IFN-γ interacts with IL-2 through distinct mechanisms to program maximal expression of effector molecules in antigen-responding T-cells, while simultaneously limiting Treg expansion.
69
A Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment
Susanne J. Szabo, Sean Kim, Gina L. Costa et al. · Cell · 2000 · 3.5K citations · Full text
A function for interleukin 2 in Foxp3-expressing regulatory T cells
Jason D. Fontenot, Jeffrey P. Rasmussen, Marc A. Gavin et al. · Nature Immunology · 2005 · 1.8K citations
Immune Response in Mice that Lack the Interferon-γ Receptor
Sui Huang, Wiljan Hendriks, Alana Althage et al. · Science · 1993 · 1.6K citations · Full text
Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin
Andrew M. Intlekofer, Naofumi Takemoto, E. John Wherry et al. · Nature Immunology · 2005 · 1.2K citations
T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells
Maryam Afkarian, John R. Šedý, Jianfei Yang et al. · Nature Immunology · 2002 · 1K citations